Intratumoral TLR-4 Agonist Injection Is Critical for Modulation of Tumor Microenvironment and Tumor Rejection | Zendy

Fábio Luiz Dal Moro Maito | Zendy; Ana Paula Duarte de Souza | Zendy; Luciana Pereira | Zendy; Megan J. Smithey | Zendy; David J. Hinrichs | Zendy; Archie Bouwer | Zendy; Cristina Bonorino | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intratumoral TLR-4 Agonist Injection Is Critical for Modulation of Tumor Microenvironment and Tumor Rejection

Author(s) -

Fábio Luiz Dal Moro Maito,

Ana Paula Duarte de Souza,

Luciana Pereira,

Megan J. Smithey,

David J. Hinrichs,

Archie Bouwer,

Cristina Bonorino

Publication year - 2012

Publication title -

isrn immunology

Language(s) - English

Resource type - Journals

eISSN - 2090-5653

pISSN - 2090-5645

DOI - 10.5402/2012/926817

Subject(s) - tumor microenvironment , melanoma , cancer research , tumor progression , immunosuppression , immunotherapy , cd8 , immune system , tumor antigen , lymph , medicine , lipopolysaccharide , immunology , chemistry , tumor cells , cancer , pathology

The tumor microenvironment shelters a complex network of mechanisms that enables local Immunosuppression to support tumor growth. In this study we found that, B16F10 melanoma growth is inversely correlated with peritumoral infiltrate cell number and with cell numbers in draining lymph nodes. Tumor growth ensued even when a foreign antigen was expressed by B16F10 cells in the presence of naive specific CD8

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research